“These in vitro data demonstrating the efficacy of SAB-185 against the Delta and Lambda variants were produced to provide new insights into antibody binding to the SARS-CoV-2 spike variants, and as a ...
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback